Use

Panorama™ is a noninvasive prenatal screening test (NIPT), using a blood-based SNP‑based technology to distinguish between maternal and fetal (placental) DNA, screening for chromosomal conditions that affect a baby's health including common trisomies (Trisomy 21, 18, 13), sex chromosome aneuploidies, triploidy, and selected microdeletions, with optional testing for fetal sex, zygosity, and fetal fraction as early as nine weeks of gestation. It is the only SNP‑based NIPT that can detect triploidy and differentiate DNA sources using >13K SNPs, validated in real‑world prospective studies with >99% sensitivity for trisomies and specific detection capabilities for 22q11.2 deletions. Panorama is a screening — not diagnostic — test; high-risk findings require confirmatory diagnostic testing such as CVS or amniocentesis. Panorama has been validated with full genetic confirmation, with zero fetal sex errors and high clinical sensitivity and PPV. Most results return within a defined timeframe after sample receipt. All decisions should involve consultation with healthcare providers. Panorama is CLIA‑certified, CAP‑accredited, ISO 13485‑certified, but not FDA‑cleared or approved. Panorama supports singleton and twin (some workflows), though some options may be unavailable for egg donor or gestational carrier pregnancies. Panorama™ screens multiple chromosomal conditions including trisomy 21/18/13, monosomy X, XXY, XXX, XYY, 22q11.2 deletion, Prader‑Willi syndrome, Angelman syndrome, 1p36 deletion, Cri‑du‑chat syndrome, and triploidy. Many conditions are detailed with background clinical context.